The British Journal of Psychiatry (2006) 189: 478. doi: 10.1192/bjp.189.5.478
© 2006 The Royal College of Psychiatrists
This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by TYRER, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by TYRER, P.

COLUMNS

PETER TYRER

APOLITICAL PSYCHIATRY

Recently at a national conference I created a storm by saying that ‘good psychiatry is apolitical’ and that we were generally lucky in the UK in being allowed to practise the way we thought was best. My critics claimed I was living in some distorted false utopia and one went so far as to suggest that I be prevented from practising in psychiatric services until I came to my senses. My arguments are simple; good practice is based on evidence, and in the end, the softly spoken voice of good data will drown the foghorns of opinion and dogma, however loudly they are blasted from the rooftops. The trouble is that the voice of good data is distorted more in psychiatry than in other disciplines. Singh & Burns (2006), for example, point out that nobody seems to suggest that the excess of diabetes in South Asians is a consequence of institutional racism yet, despite contradictory evidence (Arseneault et al, 2004; Gudjonsson et al, 2004; Morgan et al, 2005a,b), many are very keen to promote this explanation for the higher proportion of African–Caribbeans who are compulsorily admitted to psychiatric hospitals and subjected to restraint. Politics fills the gap when evidence is poor, and it is our task at the Journal to keep politics out by getting the unequivocal evidence in, and allowing all hypotheses to have acceptable status (including ones such as institutional racism) until the good data are collected and indicate a clear path forward.

Some of the difficulties in getting good evidence are illustrated well in this issue. Adams et al (pp. 391–392) suggest an unusual paradox, that rich countries may practise less evidence-based treatment than poor ones. The evidence is collected mainly in rich countries and becomes widely disseminated but, whereas economic exigencies force poor countries into better practice (e.g. Chisholm et al, 2004), richer ones are blinded by ‘clouds of dust from marketing’ and have less clear vision. Impartial head-to-head comparisons of different drugs are often lacking and so we are pleased to note that the study of McCue et al (pp. 433–440), finding clear differences between the effects of five antipsychotic drugs in schizophreniform disorders, was free of pharmaceutical company influence. But this does not mean that good evidence from company-funded studies should be ignored, and I support absolutely the statement by Thase (2002) that ‘although the funding source of a research finding should be considered when reviewing and interpreting the results of a study, hopefully our field has not become so jaded or cynical that all such work is rejected out of hand’.

The influence of selective reporting of drug effects has become a cause célèbre in the case of SSRIs in the treatment of child and adolescent depression. The clouds of unreported dust are now settling and Dubicka et al (pp. 393–398) suggest that drug-induced suicidal ideation is indeed present in this population but not to a large degree – I think we are getting close to a good final evidence base here. Other subjects are still in the early days of evidence gathering, often the most exciting phase, and it is good to report both the suggestion of the positive value of music therapy in schizophrenia (Talwar et al, pp. 405–409) and the caution the authors have exercised in extrapolating from one significant finding (p. 408), the sophisticated handling by Busse et al (pp. 399–404) of data suggesting that the progression of mild cognitive impairment to dementia is anything but an inexorable straight line, and two very different facets of the fuzzy polyhedron called the schizophrenia spectrum (Cannon et al, pp. 463–464; Van Rijn et al, pp. 459–460). These all illustrate the need to keep evidence floating in a transparent equilibrium oscillating between doubt and certainty, and free of political interference. We hope that this message will also be noted in the corridors of power when the value of crisis resolution teams is being discussed. The data of Glover et al (pp. 441–445) give some support to this initiative but their conclusions are hedged in provisos. It is puzzling that the greatest effect on admissions was in women aged between 35 and 64; is this the first independent evidence of the value of ‘a right good natter’?

PODCASTS FOR THE BRITISH JOURNAL OF PSYCHIATRY

I am keen on growing broad beans but often miss the early crop that grows close to the ground and gets covered in splashings of earth. I have always thought of these as podcasts but now understand that the word has been hijacked as ‘non-music audio broadcasts that have been converted to an MP3 file or other audio file format for playback in a digital music player’. The excitement of this new technology is now available on the Royal College of Psychiatrists’ website (see ‘what’s new’ on http://www.rcpsych.ac.uk), where selected authors are interviewed by Dr Raj Persaud about their work as it is published in the Journal. Why not try it?

REFERENCES

  1. Arseneault, L., Cannon, M., Witton, J., et al (2004) Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry, 184, 110 –117.[Abstract/Free Full Text]
  2. Chisholm, D., Sanderson, K., Ayuso-Mateos, J. L., et al (2004) Reducing the global burden of depression: population-level analysis of intervention costeffectiveness in 14 world regions. British Journal of Psychiatry, 184, 393 –403.[Abstract/Free Full Text]
  3. Gudjonsson, G. H., Rabe-Hesketh, S. & Szmukler, G. (2004) Management of psychiatric in-patient violence: patient ethnicity and use of medication, restraint and seclusion. British Journal of Psychiatry, 184, 258 –262.[Abstract/Free Full Text]
  4. Morgan, C., Mallett, R., Hutchinson, G., et al (2005a) Pathways to care and ethnicity. 1: Sample characteristics and compulsory admission. Report from the ÆSOP study. British Journal of Psychiatry, 186, 281 –289.[Abstract/Free Full Text]
  5. Morgan, C., Mallett, R., Hutchinson, G., et al (2005b) Pathways to care and ethnicity. 2: Source of referral and help-seeking. Report from the ÆSOP study. British Journal of Psychiatry, 186, 290 –296.[Abstract/Free Full Text]
  6. Singh, S. & Burns, T. (2006) Race and mental health: there is more to race than racism. BMJ, 333, 648 –651.[Free Full Text]
  7. Thase, M. E. (2002) Conflict of interest and the British Journal of Psychiatry: author’s reply (letter). British Journal of Psychiatry, 180, 82 –83.[Free Full Text]

Related articles in BJP:

The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries
CLIVE E. ADAMS, PRATHAP THARYAN, EVANDRO S. F. COUTINHO, and T. SCOTT STROUP
BJP 2006 189: 391-392. [Abstract] [Full Text]  

Suicidal behaviour in youths with depression treated with new-generation antidepressants: Meta-analysis
BERNADKA DUBICKA, SARAH HADLEY, and CHRISTOPHER ROBERTS
BJP 2006 189: 393-398. [Abstract] [Full Text]  

Progression of mild cognitive impairment to dementia: a challenge to current thinking
ANJA BUSSE, MATTHIAS C. ANGERMEYER, and STEFFI G. RIEDEL-HELLER
BJP 2006 189: 399-404. [Abstract] [Full Text]  

Music therapy for in-patients with schizophrenia: Exploratory randomised controlled trial
NAKUL TALWAR, MIKE J. CRAWFORD, ANNA MARATOS, ULA NUR, ORII McDERMOTT, and SIMON PROCTER
BJP 2006 189: 405-409. [Abstract] [Full Text]  

Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia
ROBERT E. McCUE, RUBINA WAHEED, LEONEL URCUYO, GERALDINE ORENDAIN, MICHEL D. JOSEPH, RICHARD CHARLES, and SYED M. HASAN
BJP 2006 189: 433-440. [Abstract] [Full Text]  

Crisis resolution/home treatment teams and psychiatric admission rates in England
GYLES GLOVER, GERDA ARTS, and KANNAN SURESH BABU
BJP 2006 189: 441-445. [Abstract] [Full Text]  

Klinefelter’s syndrome (karyotype 47,XXY) and schizophrenia-spectrum pathology
SOPHIE VAN RIJN, ANDRÉ ALEMAN, HANNA SWAAB, and RENÉ KAHN
BJP 2006 189: 459-461. [Abstract] [Full Text]  

Neuropsychological performance at the age of 13 years and adult schizophreniform disorder: Prospective birth cohort study
MARY CANNON, TERRIE E. MOFFITT, AVSHALOM CASPI, ROBIN M. MURRAY, HONALEE HARRINGTON, and RICHIE POULTON
BJP 2006 189: 463-464. [Abstract] [Full Text]  




This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by TYRER, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by TYRER, P.